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A 42-year-old woman, never smoker, complaining of chronic cough, underwent computed tomography that depicted 
a right lower lung mass and subcarinal lymphadenopathy. 
Disease was classified as stage IIIA lung adenocarcinoma 
(cT3N2M0), without an EGFR or KRAS mutation. After neo-
adjuvant chemotherapy with cisplatin and gemcitabine, the 
patient underwent surgery comprising a right pneumonectomy 
and a lymph node dissection. One year and a half later, she was 
diagnosed with liver metastasis. The patient was treated with 
carboplatin, pemetrexed, and bevacizumab, achieving a stable 
disease for 9 months. Fluorescence in situ hybridization was 
performed, which revealed anaplastic lymphoma kinase (ALK) 
gene rearrangement. Crizotinib (ALK inhibitor) was started at 
disease progression. Tolerance was good and a partial response 
of hepatic lesions was observed. After 38 cycles of crizotinib 
(114 weeks on therapy), because the patient complained diz-
ziness, full radiological screening showed stable liver lesions 
but brain magnetic resonance imaging revealed an appearance 
of carcinomatous meningitis associated with brain metastases. 
Lumbar punctions could not be performed because the patient 
refused. LDK378 was obtained for compassionate use and was 
started at a dose of 750 mg once daily. The treatment was well 
tolerated apart from nausea grade 2, thus the dose was reduced 
to 600 mg at day 60. The patient described rapid attenuation 
of dizziness. After 5 weeks of treatment, magnetic resonance 
imaging confirmed treatment efficacy with a decrease in brain 
lesions of 26% and in meningeal contrast (Fig. 1), that is still 
maintained after 5 and a half months.
DISCUSSION
ALK gene rearrangements occur in 3–7% of non–
small-cell lung cancer (NSCLC) and are more prevalent in 
nonsmokers, younger patients, and adenocarcinomas.1 Since 
August 2011, patients with ALK-rearranged NSCLC can be 
treated with crizotinib. Crizotinib is a potent, small molecule 
oral inhibitor of ALK, which has shown efficacy in ALK-
rearranged NSCLC with an overall response rate (ORR) of 
60.8% and a median progression-free survival duration of 9.7 
months.2 ORR to crizotinib is only 25% in brain metastasis.3 
The central nervous system (CNS) remains the dominant site 
of acquired resistance on therapy for ALK patients with or 
without brain metastasis. LDK378 (Novartis) is a new potent 
and selective oral ALK inhibitor. Tumor regression has been 
observed in ALK-positive NSCLC xenografts and even in 
crizotinib-resistant models. A phase I/II study evaluating 
LDK378 has shown promising results, with an ORR of 57% 
in crizotinib-treated patients, an ORR of 60% in crizotinib-
naive patients, and a median progression-free survival dura-
tion of 8.6 months.4 Moreover, LDK378 seems to have an 
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FIGURE 1.  Brain radiological evaluating during LDK378 
treatment.
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activity in the CNS, with a partial response on a brain metas-
tase after 6 weeks of LDK378.4 Then LDK378 is well toler-
ated with grade 1–2 nausea, diarrhea, vomiting, and fatigue 
as the common adverse events most described, as in our 
patient. Carcinomatous meningitis portends poor prognosis, 
with a median survival time after diagnosis of approximately 
6–9 weeks. Currently, our patient is alive 6 months since the 
diagnosis with improvement of symptoms and radiological 
evidence of stable disease. Moreover, another highly selec-
tive ALK inhibitor, Alectinib (Roche), has been reported to 
be active in Crizotinib-resistant carcinomatous meningitis in 
a patient included in a phase I study.5 Thus, second generation 
ALK inhibitors such as LDK378 seem to be highly efficient 
in ALK-positive NSCLC and more against CNS lesions.
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